ADHD in adults: what it’s like living with the condition – and why many still struggle to get diagnosed

Jul 2, 2021

4 min



Many of us think of ADHD (attention deficit hyperactivity disorder) as a childhood condition – which is typically when it’s diagnosed. But a growing number of people are sharing their experiences of being diagnosed with ADHD in adulthood. Social media has even played a role in this, with reports of people going to see their doctor after first learning about symptoms on TikTok. In fact, around 2.5% of adults are thought to live with ADHD – including us.


Yet despite this growing awareness, many adults continue to struggle to get a diagnosis.


ADHD is a genetic neurodevelopmental disorder, in which the brain grows differently, lacking action from specific chemicals involved in pleasure and reward. This means ADHD brains often search for ways to stimulate these chemicals, which is why people can experience inattentiveness, hyperactivity and impulsivity.


Common traits of ADHD include:


  • Not following through on longer tasks (or not starting them)
  • Getting distracted by other tasks or thoughts
  • Seeking out risk or activities that provide immediate reward
  • Restlessness (either outwardly or internally)
  • Interrupting other people (without wanting to)
  • Symptoms are similar for both adults and children, although elements of them differ or change as we age. For example, inattention is the most persistent symptom in adults.

ADHD can be debilitating and is associated with higher likelihood of lower quality of life, substance use issues, unemployment, accidental injuries, suicide and premature death. In addition, ADHD can cost adults around £18,000 per year because of things like medical care or paying for social support.


It’s also commonly associated with a wide range of co-existing conditions in adults.


For example, depression is almost three times more prevalent in adults with ADHD. And nearly half of all adults with ADHD also have bipolar spectrum disorder.


Around 70% of adults with ADHD also experience emotional dysregulation, which can make it more difficult to control emotional responses. It’s also thought that almost all adults with ADHD have rejection sensitive dysphoria, a condition where perceived rejection or criticism can cause extreme emotional sensitivity or pain.


On top of this, adults with ADHD may have poor working memory – such as being unable to remember a simple shopping list – and “time blindness” (the inability to perceive time). Some may also have oppositional defiant disorder, which means they often react poorly to perceived orders or rules.


While none of these co-existing conditions are used to diagnose ADHD, they can make ADHD feel all the more difficult to live with.



Being diagnosed


Getting an ADHD diagnosis as an adult in the UK is notoriously difficult – with reports of some people waiting up to five years.


Waiting for a diagnosis is common for adults with ADHD. Roman Kosolapov/ Shutterstock


This is because you can only be diagnosed by a specialist psychiatrist. But even with a referral to a specialist, a person has to show clear evidence of almost all ADHD traits, having had these traits since childhood, and that they’re having a serious affect on their life – such as causing issues with work, education, or maintaining relationships.


For us, our experiences of being diagnosed with ADHD aren’t all that different from what other adults have gone through.


Like many people I (Alex) was only diagnosed with ADHD “by accident” after being referred to an NHS psychiatrist to get help with (what I now know to be) alcohol self-medication. Because of my ADHD, my brain demands quite extreme inputs most of the time.


Ironically, I’ve published scientific papers on ADHD and – probably due to a classic ADHD lack of self-awareness – it didn’t cross my mind that I could have it. The “label” has since helped me move away from feeling broken toward an understanding of my behaviour.


My main challenges remain prioritising tasks based on importance (instead of excitement) and quite extreme anti-authority behaviour (sometimes called oppositional defiance). I am also a terrible spectator, struggling to attend conference talks or sit still at the theatre – it can feel like physical pain.


On the other hand, I (James) was diagnosed pretty quickly because I used a private clinic – though there was still a long wait for medication. Yet I’d known for five years before this that I probably had ADHD, but coped with it well until the pandemic. The added pressure of isolation and increased workload impacted my mental health, so I sought a diagnosis.


Now diagnosed and medicated, life is getting easier to cope with – although there are still many challenges every day. I frequently get anxiety about the silliest things, like talking to a friend, but appearing on television is fine.


On a daily basis I forget many simple things, such as where I left my keys, or that I am running a bath. I struggle immensely with controlling my emotions and with rejection especially. For example, when no one responded to a joke I made about my ADHD on a senior management messaging group I was tempted to quit my job. I am utterly unable to pay full attention in meetings or seminars and cannot control my impulse purchasing.


While there’s a growing recognition of ADHD in adults, many people still live with it undiagnosed for any number of reasons – sometimes even because they’re unaware that what they experience is actually different from other people.


Understanding the condition in adults, taking it more seriously as a disorder, raising awareness of it, and investing in services to improve diagnosis times are key. Diagnosis opens the door to treatment, which can have a marked impact on living with the disorder – such as improving self-esteem, productivity and quality of life.


This article was co-written by Dr James Brown (Aston University) and Dr Alex Connor (University of Birmingham)



Powered by

You might also like...

Check out some other posts from Aston University

Major trial shows increasing bone density fails to cut fracture risk in brittle bone disease featured image

3 min

Major trial shows increasing bone density fails to cut fracture risk in brittle bone disease

An international clinical trial involving Aston University researchers has challenged long held assumptions about how brittle bone disease is treated in adults, after finding that substantially increasing bone density did not reduce the risk of fractures. The study, published in the Journal of the American Medical Association (JAMA), examined whether a two stage treatment using the bone building drug teriparatide followed by the bone preserving drug zoledronic acid could reduce fractures in adults with osteogenesis imperfecta, often referred to as brittle bone disease, a rare genetic condition that causes bones to break easily throughout life. Researchers followed 349 adults treated at 27 specialist centres across the UK and Europe. While the treatment led to clear increases in bone density in the spine and hip, fracture rates were no lower than among patients receiving standard care, suggesting that bone quality may matter more than bone density alone in preventing fractures in people with the condition. The findings underline a key distinction between brittle bone disease and more common bone conditions such as osteoporosis, where increasing bone density is known to reduce fracture risk. In osteogenesis imperfecta, the study suggests that bones can become denser without becoming less likely to break, indicating that the underlying quality and structure of bone tissue may play a greater role in fracture risk than density alone. Dr Zaki Hassan Smith, an endocrinologist at Aston Medical School who contributed to the research, said: “This study shows that in osteogenesis imperfecta, simply increasing bone density doesn’t necessarily translate into fewer fractures. That’s important, because it tells us that the disease is more complex than what we see on a scan. The findings help shift the focus towards understanding bone quality and how bones behave in real life, which is essential if we are to develop more effective treatments that genuinely reduce harm for patients.” Osteogenesis imperfecta is a genetic condition that affects collagen, leaving bones fragile and prone to fracture throughout life. There is currently no licensed treatment specifically approved to prevent fractures in adults with the condition, and patients often experience repeated fractures, chronic pain and long term disability. The trial tested a sequential treatment strategy commonly used in osteoporosis, where a bone building drug is followed by a treatment designed to preserve gains in bone strength. Although this approach successfully increased bone density in people with osteogenesis imperfecta, it did not reduce fracture rates, suggesting that treatment strategies effective in osteoporosis may not directly translate to rare bone diseases. Researchers did observe improvements in some quality of life measures among participants receiving the treatment, including reduced pain interference and improved mobility. However, fracture prevention remained unchanged, reinforcing the need for new approaches that target the fundamental properties of bone in osteogenesis imperfecta rather than density alone. The study was led by the University of Edinburgh and funded by the Medical Research Council and the National Institute for Health and Care Research. Aston University contributed clinical and academic expertise through Aston Medical School as part of the large international collaboration, which involved specialist centres across the UK and Europe. The study was led by the University of Edinburgh, with Aston University contributing clinical and academic expertise as part of a wider international collaboration involving multiple specialist centres across the UK and Europe. The research was funded by the Medical Research Council and the National Institute for Health and Care Research. Researchers say the findings provide important guidance for future research, helping to steer efforts towards treatments that focus on bone quality, strength and resilience in everyday life. They also highlight the value of large scale clinical trials in rare diseases, where learning what does not reduce harm is an essential step towards better care. The paper, Teriparatide Plus Zoledronic Acid for Osteogenesis Imperfecta, is published in JAMA. https://doi.org/10.1001/jama.2026.6889

Why disaster recovery in the Himalayas needs a rethink featured image

3 min

Why disaster recovery in the Himalayas needs a rethink

After five weeks of fieldwork across Nepal, Bhutan and Northwest India, Aston University researcher Dr Komal Raj Aryal is calling for a more locally grounded approach to resilience and post-disaster recovery in one of the world’s most hazard-prone regions. What happens after the headlines fade from a disaster? That question sits at the heart of new field research led by Dr Komal Raj Aryal, Lecturer in Crisis and Disaster Management at Aston Business School. After returning from a five-week research visit across Nepal, Bhutan and Northwest India, Dr Aryal says the evidence points to a troubling reality: many communities remain highly vulnerable long after major recovery programmes are supposed to have helped them rebuild. The trip brought together field visits, stakeholder consultations and community observations linked to ongoing UKRI, NERC and ISPF-supported research on earthquake risk, disaster governance, resilience and post-disaster recovery in the Himalayan region. The aim was not only to understand current conditions, but to ask why repeated losses continue despite years of international development assistance, scientific research and investment. Across the region, the research found that resilience is being undermined by a combination of persistent governance challenges, fragmented institutions, weak local preparedness systems, livelihood insecurity and mounting environmental pressures. In other words, recovery is not simply about rebuilding infrastructure; it is about whether communities are genuinely better equipped to cope with the next shock. This challenge is especially striking in places still living with the legacy of the 2015 Nepal earthquakes, where long-term vulnerabilities remain visible despite the scale of international support directed towards recovery and reconstruction. Reflecting on his findings, Dr Aryal said: “One of the most striking observations from the field is that many communities affected by the 2015 Nepal Earthquakes continue to face similar vulnerabilities today, despite significant international support allocated for recovery and reconstruction. This raises important questions about how disaster recovery is planned, implemented, and sustained over time.” The fieldwork also highlighted the growing complexity of future disaster risks in the Himalayas. Large-scale earthquakes do not exist in isolation; they interact with environmental degradation, cascading hazards, climate-related stresses and rapid urbanisation in fragile mountain settings. He added: “The Himalayan region is entering a period of growing uncertainty where environmental change, socio-economic inequality, weak governance systems, and seismic risks are becoming increasingly interconnected. There is an urgent need to rethink conventional development approaches and invest more seriously in locally grounded, community-centred resilience strategies.” For Aston University, this work reflects a broader commitment to international research on disaster risk reduction, resilience governance and humanitarian response across South Asia. Aston researchers are working with government agencies, local authorities, universities, emergency responders and humanitarian organisations to strengthen evidence-based approaches to preparedness and recovery. The findings feed into wider international debates about sustainable development, climate resilience, risk communication and the future of disaster governance in vulnerable mountain regions. They also underline the importance of moving beyond short-term recovery models towards approaches that are participatory, practical and rooted in local knowledge. Dr Aryal’s research emphasises the value of integrating community knowledge, participatory governance, youth engagement and long-term livelihood security into resilience planning. As future collaborations and policy discussions develop, these themes are likely to be central to how the region prepares for the risks ahead. The recent fieldwork is expected to inform future international research partnerships, policy dialogue and resilience-focused initiatives between the UK and South Asian partners.

Aston University economists say Prime Minister can reduce UK trade vulnerability with China visit featured image

2 min

Aston University economists say Prime Minister can reduce UK trade vulnerability with China visit

Greenland episode exposed UK’s lack of effective response to economic coercion from allies Research shows tariff retaliation would have cost the average UK household up to £324 per year Economists say China visit is “portfolio risk management” – diversification reduces vulnerability. The Prime Minister’s visit to China – the first by a British PM since 2018 – is an opportunity to reduce the UK’s vulnerability to economic coercion, according to new research from Aston University. A policy paper from Aston Business School’s Centre for Business Prosperity analyses the January 2026 Greenland tariff episode, when President Trump threatened and then withdrew tariffs on eight European countries. The researchers found that the UK had no good options: retaliation would have made Britain worse off, while absorbing the tariffs left Europe without credible deterrence. Director of the centre for business prosperity, Professor Jun Du, said: “The Greenland episode was a wake-up call. When your principal security ally threatens economic coercion, the old assumptions about who is safe and who is dangerous no longer hold. “The PM’s China visit should be framed as portfolio risk management – building diversified trading relationships that reduce the UK’s exposure to any single partner. Just as investors don’t put all their money in one stock, countries shouldn’t put all their trade into one basket. A UK with multiple strong partnerships is harder to pressure, whether the pressure comes from Washington or Beijing.” The research found that coordinated UK–EU tariff retaliation would have cost British households up to £324 per year – the worst outcome modelled. But the authors argue that Europe has untapped leverage elsewhere: the US runs a €148 billion annual services surplus with the EU, and mutual investment exceeds €5.3 trillion. Associate professor of economics and co-author, Dr Oleksandr Shepotylo, said: “Tariff retaliation fails because it hurts consumers and distorts the economy – the retaliator suffers similarly to the target. But Europe has cards it isn’t playing. Services, investment screening, and regulatory access are pressure points where Europe can respond effectively.” UK exports to China fell by 10.4% in the year to Q2 2025, with goods exports down 23.1% – the sharpest decline among major trading partners. The researchers argue that this closes off the UK’s largest alternative market at precisely the moment US reliability is in question. The paper identifies three priorities for UK policy: Recognise the permanent incentives behind US tariffs. US tariff revenue hit $264 billion in 2025. Trade negotiations alone cannot resolve revenue-driven policy. Build UK–EU coordination on non-tariff instruments. Services, investment, procurement, and regulation offer leverage that tariffs do not. Treat China engagement as portfolio risk management. Concentration in any single market creates vulnerability. Diversification is not about picking sides – it’s about resilience. Professor Du added: “The question for the Prime Minister is whether to use this breathing space to build resilience – or wait for the next Greenland.” To read the policy paper in full, click on this link:

View all posts